Pavia

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis4 trials
• Acute myeloid leukaemia1 trial
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• Epilepsy1 trial
• High blood pressure1 trial
• Myeloproliferative neoplasms1 trial
• Pulmonary arterial hypertension1 trial
• Thalassaemia1 trial

Phase

• Phase 33 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Novartis Pharmaceuticals7 trials

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

  NCT06345157· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

  NCT02962414· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Multiple sclerosis1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

  NCT05376579· Novartis Pharmaceuticals· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source